The effectiveness of computerized cognitive training program for older adults with mild cognitive impairment and early dementia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0009281

Enrollment

Registered

2024-03-29

Start date

2020-12-23

Completion date

Unknown

Last updated

2024-04-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Others(Cognitive intervention) : ? After selecting subjects, groups are divided into those who will receive computerized cognitive training (conventional treatment + cognitive training) and those who

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Subjects diagnosed with mild cognitive impairment according to Petersen’s criteria (Petersen et al., 1999) or early stage of major neurocognitive disorder according to DSM-5 (American Psychiatric Association, 2013) 2. Korean male or female over 60 years of age 3. Subjects with Clinical dementia rating global scale = 1 4. Subjects whose existing treatment (medication or face-to-face treatment) can be confirmed (existing treatment itself is irrelevant) 5. Subjects for whom no other structural causes of cognitive decline were found in brain MRI 6. After hearing and fully understanding the detailed explanation of this clinical trial, the subject voluntarily decided to participate and signed the consent form to comply with the precautions.

Exclusion criteria

Exclusion criteria: 1. Subjects with mental illness other than mild cognitive impairment and early Alzheimer's disease (schizophrenia, bipolar disorder, depression, etc.) 2. Subjects diagnosed with or accompanied by cognitive decline due to other degenerative brain diseases, infections of the central nervous system (HIV, syphilis, etc.), head trauma, Creutzfeld-Jacob disease, Pick's disease, Huntington's disease, and Parkinson's disease 3. Subjects diagnosed with vascular dementia according to DSM-5 (American Psychiatric Association, 2013) criteria 4. Subjects with a history of stroke within 1 year of participating in the trial 5. Subjects who have participated in other treatment studies, including drugs, within 3 months before the start of the clinical trial (week 0) 6. Those who cannot undergo tests (e.g. fMRI) conducted during the clinical trial period 7. Cancer patients (systemic cancer including brain tumor) 8. Drug/alcohol abuser 9. Other subjects deemed unsuitable by researchers to participate in clinical trials

Design outcomes

Primary

Measure	Time frame
MMSE;RCFT copy and recall test;Boston Naming test;Seoul Verbal Learning test;Word fluency test;Trail Making test;Stroop test	—

Secondary

Measure	Time frame
apathy scale;Positive and negative affect scale;Geriatric depression scale;Quality of life scale;Mild behavioral impairment checklest and neuropsychiaric inventory;Usability scale	—

Countries

Korea, Republic of

Contacts

Public ContactJae Myeong Kang

Gachon University Gil Medical Center

kangzam@hanmail.net+82-32-460-2299

Outcome results